Jaguar Health, Inc. (NASDAQ:JAGX) headquartered in San Francisco, will host a conference call for the investment community to discuss the 3Q20 financial results on 16th November 2020 at 8:30 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website jaguar.health
To participate on the live call, please dial 866-548-4713 or 323-794-2093 (International), and the passcode is 8490376
Earnings Expectation
Jaguar Health, Inc. is expected to report third quarter earnings results, before market open, on Monday 16th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.11 per share from revenue of $ 7.80 million. Looking ahead, the full year loss are expected at $ 0.69 per share on the revenues of $ 23.47 million.
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome – diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera.
